Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27388123 | 1.00 | MGLL (0.43) | MGLLLMNAPKMGSK3AGSK3B | |
| SCHEMBL24797571 | 1.00 | MGLL (0.43) | MGLLLMNAPKMGSK3AGSK3B | |
| SCHEMBL22311942 | 1.00 | MGLL (0.43) | MGLLLMNAPKMGSK3AGSK3B | |
| SCHEMBL13541914 | 0.92 | LMNA (0.47) | MGLLLMNAPKMGSK3AGSK3B | |
| SCHEMBL24797572 | 0.91 | MGLL (0.43) | MGLLLMNAPKMGSK3AGSK3B | |
| SCHEMBL20338051 | 0.88 | LMNA (0.45) | MGLLLMNAPKMGSK3AGSK3B | |
| SCHEMBL25415474 | 0.87 | GSK3A (0.47) | MGLLLMNAPKMGSK3AGSK3B | |
| SCHEMBL20677209 | 0.87 | MGLL (0.42) | MGLLLMNAPKMGSK3AGSK3B | |
| SCHEMBL20677173 | 0.87 | GSK3A (0.44) | MGLLLMNAPKMGSK3AGSK3B | |
| SCHEMBL18470775 | 0.87 | GSK3A (0.44) | MGLLLMNAPKMGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417486-A1 | ASYMMETRIC BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4412660-A1 | ASYMMETRIC BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240197899-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-20230263903-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230263903-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2023059544-A1 | ASYMMETRIC BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-4108675-A1 | PREPARATION AND USE OF IMMUNOSTIMULATORY COUPLING COMPLEX WHICH IS DELIVERED AND ACTIVATED IN TARGETED MANNER | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. (CN) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022036101-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263903-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | KCNJ5, IL5, CYP3A5 | MGLL 4668/4885LMNA 4529/4885PKM 1482/4885 |
| US-20240417486-A1 | ASYMMETRIC BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES AND USES THEREOF | STING1, BID, MAVS | MGLL 887/4885LMNA 2104/4885PKM 2987/4885 |
| US-20240197899-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | AADAC, BRD4, IDO2 | MGLL 4030/4885LMNA 3537/4885PKM 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.